Spots Global Cancer Trial Database for recurrent prostate cancer
Every month we try and update this database with for recurrent prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | NCT00667641 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Prostate Cancer Unspecified Adu... | bortezomib paclitaxel | 18 Years - | Rutgers, The State University of New Jersey | |
| Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | NCT01220973 | Prostate Cancer | atorvastatin ca... celecoxib laboratory biom... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors | NCT00471432 | Bladder Cancer Breast Cancer Kidney Cancer Lung Cancer Ovarian Cancer Prostate Cancer Unspecified Adu... | custirsen sodiu... docetaxel pharmacological... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer | NCT00032006 | Prostate Cancer | brachytherapy radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | NCT00079001 | Metastatic Canc... Prostate Cancer | zoledronic acid placebo androgen depriv... GnRH agonist Calcium supplem... Vitamin D | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer | NCT00967889 | Prostate Cancer | gene expression... protein analysi... biologic sample... laboratory biom... | - | National Cancer Institute (NCI) | |
| Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients | NCT01882985 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... | Docetaxel Lycopene | 21 Years - | University of California, Irvine | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer | NCT00423475 | Prostate Cancer | goserelin aceta... adjuvant therap... radiation thera... | 18 Years - 120 Years | UNICANCER | |
| SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy | NCT05044754 | Cryotherapy High Intensity ... Recurrent Prost... | Local treatment... | 18 Years - 90 Years | University Hospital Virgen de las Nieves | |
| Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) | NCT00005039 | Adenocarcinoma ... Recurrent Prost... Stage IV Prosta... | recombinant fow... recombinant vac... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer | NCT00005028 | Prostate Cancer | bryostatin 1 paclitaxel | 18 Years - | University of Maryland, Baltimore | |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | NCT02184533 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... Multiple Myelom... Plasmacytoma | sodium selenite radiation thera... laboratory biom... pharmacological... questionnaire a... | 18 Years - | Stanford University | |
| Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy | NCT00559481 | Prostate Cancer | dexamethasone ketoconazole therapeutic hyd... pharmacological... | - | Roswell Park Cancer Institute | |
| Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | NCT00002775 | Prostate Cancer | docetaxel estramustine ph... | 18 Years - | National Cancer Institute (NCI) | |
| PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802 | NCT01672905 | Prostate Cancer | laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer | NCT00039104 | Adenocarcinoma ... Recurrent Prost... Stage IV Prosta... | rebimastat zoledronic acid laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00110214 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | docetaxel placebo prednisone bevacizumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00017576 | Prostate Cancer | calcitriol carboplatin | 18 Years - 120 Years | OHSU Knight Cancer Institute | |
| Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy | NCT02050906 | Recurrent Prost... Stage IV Prosta... | behavioral diet... exercise interv... behavioral acti... telephone based... quality-of-life... questionnaire a... | - | Ohio State University Comprehensive Cancer Center | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy | NCT00002924 | Prostate Cancer | mutation analys... | - | Alliance for Clinical Trials in Oncology | |
| S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin | NCT01120262 | Prostate Cancer | gene expression... polymorphism an... laboratory biom... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00483561 | Prostate Cancer | Gefitinib plus ... | 19 Years - 120 Years | University of Nebraska | |
| Trastuzumab in Treating Patients With Prostate Cancer | NCT00003740 | Prostate Cancer | trastuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy | NCT00309894 | Prostate Cancer | sargramostim ketoconazole therapeutic hyd... | - 120 Years | University of California, San Francisco | |
| Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery | NCT01912820 | Adenocarcinoma ... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | green tea extra... quercetin placebo therapeutic con... laboratory biom... | 40 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00005810 | Prostate Cancer | filgrastim carboplatin docetaxel estramustine ph... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer | NCT00454571 | Recurrent Prost... | pazopanib hydro... leuprolide acet... goserelin aceta... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | NCT00002775 | Prostate Cancer | docetaxel estramustine ph... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer | NCT00095667 | Recurrent Prost... Stage IV Prosta... | lapatinib ditos... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | NCT00074022 | Recurrent Non-s... Recurrent Prost... Stage III Prost... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... Stage IV Prosta... Unspecified Adu... | GTI-2040 docetaxel laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer | NCT00293371 | Prostate Cancer | docetaxel prednisone vatalanib | 18 Years - | University of California, San Francisco | |
| Isotretinoin, Interferon Alfa-2b, Docetaxel, and Estramustine in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00176527 | Prostate Cancer | recombinant int... docetaxel estramustine ph... isotretinoin polyacrylamide ... protein express... immunohistochem... | 18 Years - | Rutgers, The State University of New Jersey | |
| Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer | NCT00670046 | Prostate Cancer | valproic acid standard of car... | 18 Years - 85 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases | NCT00081159 | Metastatic Canc... Prostate Cancer | Doxorubicin hyd... Goserelin aceta... Leuprolide acet... Zoledronic acid orchiectomy strontium chlor... | - | M.D. Anderson Cancer Center | |
| Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer | NCT00093457 | Prostate Cancer | sorafenib tosyl... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Biological Therapy in Treating Patients With Prostate Cancer | NCT00039299 | Prostate Cancer | therapeutic aut... | - | National Cancer Institute (NCI) | |
| Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer | NCT00182741 | Prostate Cancer | calcitriol mitoxantrone hy... prednisone | 18 Years - 100 Years | OHSU Knight Cancer Institute | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00524589 | Prostate Cancer | calcitriol dexamethasone protein express... laboratory biom... | - 120 Years | Roswell Park Cancer Institute | |
| S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00433446 | Prostate Cancer | CNTO 328 | 18 Years - | SWOG Cancer Research Network | |
| Bipolar Androgen-based Therapy for Prostate Cancer (BAT) | NCT01750398 | Recurrent Prost... | Testosterone cy... Goserelin Leuprolide | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Plasma and Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled on Clinical Trials CALGB-9480 or CALGB-9583 | NCT00898833 | Prostate Cancer | laboratory biom... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy | NCT00559481 | Prostate Cancer | dexamethasone ketoconazole therapeutic hyd... pharmacological... | - | Roswell Park Cancer Institute | |
| Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer | NCT00036933 | Prostate Cancer | MUC-2-Globo H-K... QS21 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | NCT00028769 | Prostate Cancer | bicalutamide estramustine etoposide flutamide goserelin leuprolide nilutamide paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy | NCT00073970 | Prostate Cancer | celecoxib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer | NCT00030277 | Prostate Cancer | high-intensity ... | 40 Years - 80 Years | National Cancer Institute (NCI) | |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma | NCT00082823 | Cancer | ziv-aflibercept | 18 Years - 120 Years | Regeneron Pharmaceuticals | |
| Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer | NCT00796458 | Pain Prostate Cancer | docetaxel releasing hormo... | 18 Years - | National Cancer Institute (NCI) | |
| AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00513071 | Hormone-resista... Recurrent Prost... | saracatinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer | NCT00003439 | Cancer | recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | NCT00079001 | Metastatic Canc... Prostate Cancer | zoledronic acid placebo androgen depriv... GnRH agonist Calcium supplem... Vitamin D | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | NCT00570700 | Hormone-refract... Adenocarcinoma ... Hormone-resista... Prostate Cancer Recurrent Prost... | Dasatinib | 18 Years - | University of California, Irvine | |
| Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | NCT02184533 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... Multiple Myelom... Plasmacytoma | sodium selenite radiation thera... laboratory biom... pharmacological... questionnaire a... | 18 Years - | Stanford University | |
| Docetaxel in Treating Patients With Relapsed Prostate Cancer | NCT00482274 | Prostate Cancer | docetaxel | 18 Years - | OHSU Knight Cancer Institute | |
| Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | NCT00330161 | Recurrent Prost... Stage IV Prosta... | vorinostat laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Calcitriol in Treating Patients With a Rising PSA Level Following Treatment for Prostate Cancer | NCT00004043 | Prostate Cancer | calcitriol | 18 Years - 120 Years | OHSU Knight Cancer Institute | |
| Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01866423 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | orteronel laboratory biom... | 18 Years - | University of Southern California | |
| Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer | NCT00003674 | Breast Cancer Colorectal Canc... Lung Cancer Prostate Cancer Veno-occlusive ... | dalteparin standard therap... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer | NCT00004071 | Prostate Cancer | leflunomide mitoxantrone hy... prednisone | 18 Years - | Pfizer | |
| Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00058253 | Recurrent Prost... Stage IV Prosta... Unspecified Adu... | tanespimycin docetaxel | 18 Years - | National Cancer Institute (NCI) | |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | NCT00031681 | Advanced Adult ... Carcinoma of th... Estrogen Recept... Extensive Stage... Gastrointestina... HER2-negative B... Metastatic Gast... Ovarian Sarcoma Ovarian Stromal... Progesterone Re... Recurrent Adeno... Recurrent Adult... Recurrent Anal ... Recurrent Basal... Recurrent Borde... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Endom... Recurrent Esoph... Recurrent Esthe... Recurrent Extra... Recurrent Gallb... Recurrent Gastr... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Non-s... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Saliv... Recurrent Small... Recurrent Small... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Small Intestine... Small Intestine... Small Intestine... Stage IV Adenoi... Stage IV Anal C... Stage IV Basal ... Stage IV Border... Stage IV Breast... Stage IV Colon ... Stage IV Endome... Stage IV Esopha... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Midlin... Stage IV Mucoep... Stage IV Non-sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Prosta... Stage IV Rectal... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Stage IVA Cervi... Stage IVB Cervi... Triple-negative... Unresectable Ex... Unresectable Ga... Unspecified Adu... Untreated Metas... | 7-hydroxystauro... irinotecan hydr... diagnostic labo... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00015977 | Prostate Cancer | PSA prostate ca... recombinant int... | 18 Years - | University of Chicago | |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | NCT03602079 | HER2-positive B... HER2 Gene Mutat... HER-2 Gene Ampl... HER2 Positive G... Salivary Gland ... Salivary Gland ... Salivary Gland ... Salivary Gland ... Lung Cancer Colo-rectal Can... Rare Diseases Solid Tumor Recurrent Gastr... Recurrent Colon... Recurrent Breas... Head and Neck C... Head and Neck C... Bladder Cancer Cervical Cancer Liver Cancer Bile Duct Cance... Urologic Cancer Pancreatic Canc... Prostate Cancer Recurrent Prost... Rectal Cancer Recurrent Ovari... Recurrent Renal... Rectal Cancer S... Rectal Cancer S... Rectal Cancer S... Skin Cancer Mouth Cancer Lip Cancer Stag... Tongue Cancer Breast Neoplasm... Larynx Cancer Tonsil Cancer Palate Cancer Mucoepidermoid ... Primary Periton... Mucinous Adenoc... Mucinous Breast... Cholangiocarcin... | A166 | 18 Years - | Klus Pharma Inc. | |
| Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | NCT01469338 | Diarrhea Hormone-resista... Recurrent Prost... Stage I Prostat... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | cabazitaxel prednisone octreotide pamo... questionnaire a... octreotide acet... | 18 Years - | University of Southern California | |
| Surgery in Treating Patients With Prostate Cancer | NCT00002938 | Prostate Cancer | conventional su... | - 75 Years | Alliance for Clinical Trials in Oncology | |
| Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases | NCT00390468 | Metastatic Canc... Pain Prostate Cancer | Tandutinib | 18 Years - | National Cancer Institute (NCI) | |
| GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | NCT00074022 | Recurrent Non-s... Recurrent Prost... Stage III Prost... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... Stage IV Prosta... Unspecified Adu... | GTI-2040 docetaxel laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer | NCT00059943 | Breast Cancer Lung Cancer Prostate Cancer | docetaxel | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy | NCT00589420 | Prostate Cancer | docetaxel sorafenib tosyl... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers | NCT00984919 | Prostate Cancer | high performanc... laboratory biom... mass spectromet... | 40 Years - 120 Years | Barbara Ann Karmanos Cancer Institute | |
| Collection of Patient-Reported Symptoms and Performance Status Via the Internet | NCT00417040 | Prostate Cancer Breast Cancer Lung Cancer Colorectal Canc... Leukemia Multiple Myelom... | internet-based ... assessment of t... Questionnaire A... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer | NCT01243385 | Prostate Cancer | Metformin | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer | NCT00967889 | Prostate Cancer | gene expression... protein analysi... biologic sample... laboratory biom... | - | National Cancer Institute (NCI) | |
| Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer | NCT00002775 | Prostate Cancer | docetaxel estramustine ph... | 18 Years - | National Cancer Institute (NCI) | |
| Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer | NCT00989105 | Prostate Cancer | immunohistochem... laboratory biom... pharmacological... computed tomogr... magnetic resona... single photon e... technetium Tc 9... | 18 Years - | Cancer Research UK | |
| Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer | NCT00059943 | Breast Cancer Lung Cancer Prostate Cancer | docetaxel | 65 Years - | Memorial Sloan Kettering Cancer Center | |
| PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802 | NCT01672905 | Prostate Cancer | laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
